Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib +/- Bevacizumab Maintenance in Advanced Ovarian Cancer
NCT05183984Phase 2Recruiting
- Sponsor
- ARCAGY
- Start
- Feb 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of bevacizumab in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by ARCAGY. Started Feb 2022; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05183984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183984.